Gastrointestinal Cancers

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

National Clinical Trial ID:: NCT07291076(opens in a new tab)
Protocol ID:: VICCGIP25073
Primary Investigator:: Thatcher Heumann
Phase:: I/II
Age Group:: Adults
Genders Eligible:: All
Drug:: Atezolizumab, Bevacizumab, Ipilimumab, Pumitamig
Cancer Type:: Gastrointestinal Cancers

Overview

The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)

Who Can Participate

Inclusion Criteria

Participants must have a histologically confirmed diagnosis of locally advanced or unresectable Hepatocellular Carcinoma (HCC).

Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Participants must have no prior systemic therapy for advanced/ unresectable HCC.

Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Exclusion Criteria

Participants must not have significant bleeding or coagulation disorders or other obvious bleeding risk evidence.

Participants must not have an organ transplant or autoimmune disease.

Other protocol-defined Inclusion/Exclusion criteria apply.

Disclaimer

This summary is based on publicly available information from clinicaltrials.gov and is intended to help patients discuss possible trial options with their oncology care team. ClinicalTrials.gov and related public listings do not independently review or approve the safety and scientific merit of every study.

Participation decisions can be made only after review by the study team and your treating clinician.